Follow The Filings

Opaleye Management Inc. James Silverman

Boston, MA 23 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $1.1B
  • 58 holdings
  • 2026 Q2
  • +45.5% QoQ
  • Top 5 46.8%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 58 holdings

Top 5 46.8%, top 10 64.8%

  1. LQDA, Liquidia 17.7%
  2. ETON, Eton Pharmaceuticals 9.4%
  3. HROW, Harrow 9.2%
  4. IRON, Disc Medicine 5.7%
  5. URGN, Urogen 4.8%
  6. APGE, Apogee Therapeutics 4.7%
  7. MGTX, Meiragtx 4.3%
  8. SLGL, Sol-Gel Technologies 3.3%
  9. RZLT, Rezolute 3.0%
  10. TGTX, TG Therapeutics 2.7%
  11. IMMX, Immix Biopharma 2.2%
  12. CBIO, Crescent Biopharma 2.1%
  13. Other 30.9%

AUM over time

2026 Q2 $1.1B +45.5% QoQ
2021 Q3: $535M 2021 Q3: $535M
Q3 2021
2021 Q4: $471M, −12.0% QoQ 2021 Q4: $471M, −12.0% QoQ
Q4
2022 Q1: $322M, −31.6% QoQ 2022 Q1: $322M, −31.6% QoQ
Q1 2022
2022 Q2: $222M, −31.1% QoQ 2022 Q2: $222M, −31.1% QoQ
Q2
2022 Q3: $242M, +9.0% QoQ 2022 Q3: $242M, +9.0% QoQ
Q3
2022 Q4: $288M, +19.0% QoQ 2022 Q4: $288M, +19.0% QoQ
Q4
2023 Q1: $334M, +16.0% QoQ 2023 Q1: $334M, +16.0% QoQ
Q1 2023
2023 Q2: $418M, +25.1% QoQ 2023 Q2: $418M, +25.1% QoQ
Q2
2023 Q3: $307M, −26.6% QoQ 2023 Q3: $307M, −26.6% QoQ
Q3
2023 Q4: $376M, +22.5% QoQ 2023 Q4: $376M, +22.5% QoQ
Q4
2024 Q1: $437M, +16.2% QoQ 2024 Q1: $437M, +16.2% QoQ
Q1 2024
2024 Q2: $438M, +0.2% QoQ 2024 Q2: $438M, +0.2% QoQ
Q2
2024 Q3: $600M, +37.0% QoQ 2024 Q3: $600M, +37.0% QoQ
Q3
2024 Q4: $571M, −4.8% QoQ 2024 Q4: $571M, −4.8% QoQ
Q4
2025 Q1: $449M, −21.4% QoQ 2025 Q1: $449M, −21.4% QoQ
Q1 2025
2025 Q2: $499M, +11.1% QoQ 2025 Q2: $499M, +11.1% QoQ
Q2
2025 Q3: $707M, +41.7% QoQ 2025 Q3: $707M, +41.7% QoQ
Q3
2025 Q4: $758M, +7.2% QoQ 2025 Q4: $758M, +7.2% QoQ
Q4
2026 Q1: $759M, +0.1% QoQ 2026 Q1: $759M, +0.1% QoQ
Q1 2026
2026 Q2: $1.1B, +45.5% QoQ 2026 Q2: $1.1B, +45.5% QoQ
Q2

Book

2024 Q4 2024 Q3, filed 14 Feb, long equity only

Download CSV Download Excel All activity
HROW, Harrow Health 23.43% Hold 3,990,000 $33.55 $134M — —
TGTX, TG Therapeutics 11.90% Reduce −0.9% 2,260,000 $30.10 $68M −20,000 +$15M
CDXS, Codexis 7.38%, was 4.51% Add +0.8% 8,840,000 $4.77 $42M +70,000 +$15M
ETON, Eton Pharmaceuticals 6.65%, was 2.78% Add +2.6% 2,852,070 $13.32 $38M +72,070 +$21M
OCUL, Ocular Therapeutix 6.49%, was 7.29% Reduce −13.6% 4,342,500 $8.54 $37M −682,500 −$6.6M
ARVN, Arvinas 5.89%, was 5.16% Add +29.5% 1,625,000 $20.70 $34M +370,000 +$2.7M
RYTM, Rhythm Pharmaceuticals 4.90% Hold 500,000 $55.98 $28M — —
Immunome 3.79%, was 3.02% Add +64.8% 2,040,000 $10.62 $22M +802,500 +$3.6M
LQDA, Liquidia 3.49% Hold 1,698,142 $11.76 $20M — —
EWTX, Edgewise Therapeutics 2.24%, was 2.33% Reduce −8.1% 480,000 $26.70 $13M −42,500 −$1.1M
DNA, Ginkgo Bioworks 2.06%, was 1.11% Add +46.3% 1,200,000 $9.82 $12M +379,798 +$5.1M
Cargo Therapeutics 1.89% Add +38.5% 750,000 $14.42 $11M +208,563 −$1M
Protara Therapeutics 1.69%, was 0.51% Add +8.6% 1,825,000 $5.28 $9.6M +143,846 +$6.6M
TRVI, Trevi Therapeutics 1.67% Reduce −9.8% 2,317,500 $4.12 $9.5M −250,490 +$971K
Jasper Therapeutics 1.50%, was 1.11% Add +13.2% 400,000 $21.38 $8.6M +46,500 +$1.9M
NAMS 1.46% Reduce −3.0% 325,000 $25.70 $8.4M −10,000 +$2.8M
Acelyrin 1.26% Add +18.0% 2,235,000 $3.21 $7.2M +341,340 −$2.2M
NRIX, Nurix Therapeutics 1.25%, was 1.57% Reduce −9.9% 378,500 $18.84 $7.1M −41,500 −$2.3M
XOMA 1.15% Hold 250,000 $26.28 $6.6M — —
PCVX, Vaxcyte 1.07%, was 1.62% Reduce −11.8% 75,000 $81.86 $6.1M −10,000 −$3.6M
ZNTL, Zentalis Pharmaceuticals 0.94%, was 0.59% Add +82.8% 1,767,500 $3.03 $5.4M +800,500 +$1.8M
Biodesix 0.93%, was 1.16% Reduce −9.2% 3,465,000 $1.53 $5.3M −350,000 −$1.7M
NUVL, Nuvalent 0.80%, was 1.09% Reduce −8.6% 58,500 $78.28 $4.6M −5,500 −$2M
Gossamer Bio 0.71%, was 0.62% Add +22.5% 4,490,000 $0.9046 $4.1M +824,990 +$356K
PTGX, Protagonist Therapeutics 0.71% Hold 105,000 $38.60 $4.1M — —
Holding 0.69% New 2,209,998 $1.79 $4M +2,209,998 +$4M
ABCL, Abcellera Biologics 0.49%, was 0.35% Add +20.6% 965,000 $2.93 $2.8M +165,000 +$747K
URGN, Urogen 0.41%, was 0.86% Reduce −45.6% 220,000 $10.65 $2.3M −184,100 −$2.8M
RZLT, Rezolute 0.40% Reduce −0.3% 465,000 $4.90 $2.3M −1,563 +$16K
Immatics 0.21% New 165,000 $7.11 $1.2M +165,000 +$1.2M
IBIO 0.16% Hold 375,000 $2.45 $919K — —
LXEO, Lexeo Therapeutics 0.15% New 130,000 $6.58 $855K +130,000 +$855K
REGENXBIO 0.11% New 80,000 $7.73 $618K +80,000 +$618K
Ventyx Biosciences 0.11% New 280,000 $2.19 $613K +280,000 +$613K
PEPG, Pepgen 0.07%, was 0.26% Reduce −38.6% 110,000 $3.79 $417K −69,200 −$1.1M
STOK, Stoke Therapeutics 0.05% New 25,000 $11.03 $276K +25,000 +$276K
ADGM, Adagio Medical 0.02% Hold 110,571 $1.05 $116K — —

Exits / last held

Gone since 2024 Q3, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
Keros Therapeutics 3.83% Exit 0 $58.07 $23M −395,276 −$23M
APLT, Applied Therapeutics Inc' 1.87% Exit 0 $8.50 $11M −1,320,000 −$11M
CYTK, Cytokinetics 0.66% Exit 0 $52.80 $4M −75,300 −$4M
Catalyst Pharmaceuticals 0.37% Exit 0 $19.88 $2.2M −112,500 −$2.2M
Lyell Immunopharma 0.32% Exit 0 $1.38 $1.9M −1,395,000 −$1.9M
Allakos 0.26% Exit 0 $0.6533 $1.6M −2,407,600 −$1.6M
RLMD, Relmada Therapeutics 0.26% Exit 0 $3.24 $1.6M −480,000 −$1.6M
Revance Therapeutics 0.24% Exit 0 $5.19 $1.4M −275,000 −$1.4M
Syros Pharmaceuticals 0.23% Exit 0 $2.15 $1.4M −654,943 −$1.4M
Aerovate Therapeutics 0.15% Exit 0 $2.09 $920K −440,000 −$920K
Regulus Therapeutics 0.14% Exit 0 $1.57 $840K −535,000 −$840K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2024 Q3. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 58 $1.1B +45.5% 13F-HR 8/14/2026 000142050626001803
2026 Q1 54 $759M +0.1% 13F-HR 5/15/2026 000142050626001151
2025 Q4 54 $758M — RESTATEMENT 4/13/2026 000149315226016299
2025 Q4 54 $758M +7.2% 13F-HR 2/17/2026 000149315226007085
2025 Q3 43 $707M +41.7% 13F-HR 11/14/2025 000149315225023429
2025 Q2 41 $494M — RESTATEMENT 8/15/2025 000164117225024301
2025 Q2 41 $499M +11.1% 13F-HR 8/14/2025 000164117225023977
2025 Q1 45 $449M −21.4% 13F-HR 5/15/2025 000164117225010914
2024 Q4 39 $571M −4.8% 13F-HR 2/14/2025 000149315225006852
2024 Q3 44 $600M +37.0% 13F-HR 11/14/2024 000149315224045811
2024 Q2 51 $438M +0.2% 13F-HR 8/14/2024 000149315224032150
2024 Q1 52 $459M — RESTATEMENT 5/29/2024 000149315224021780
2024 Q1 51 $437M +16.2% 13F-HR 5/15/2024 000149315224019869
2023 Q4 47 $376M +22.5% 13F-HR 2/14/2024 000149315224006653
2023 Q3 41 $307M −26.6% 13F-HR 11/15/2023 000149315223041364
2023 Q2 47 $418M +25.1% 13F-HR 8/14/2023 000149315223028636
2023 Q1 41 $334M +16.0% 13F-HR 5/15/2023 000149315223016769
2022 Q4 40 $288M +19.0% 13F-HR 2/10/2023 000149315223004277
2022 Q3 42 $242M +9.0% 13F-HR 11/14/2022 000149315222032068
2022 Q2 47 $222M −31.1% 13F-HR 8/15/2022 000149315222022856
2022 Q1 45 $322M −31.6% 13F-HR 5/16/2022 000149315222013764
2021 Q4 39 $471M −12.0% 13F-HR 2/14/2022 000149315222004434
2021 Q3 48 $535M — 13F-HR 11/16/2021 000149315221028799

About

Opaleye Management Inc.

23 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
Opaleye Management Inc.
Notable person
James Silverman
Location
Boston, MA
All SEC filings
View on sec.gov